{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:14:18Z","timestamp":1775484858414,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To investigate the cost-effectiveness of adding azithromycin to standard cephalosporin regimens of cesarean delivery prophylaxis by considering the maternal outcomes in the current and potential subsequent pregnancies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>A cost-effectiveness model was created using TreeAge to compare the outcomes of using azithromycin\u2013cephalosporin with cephalosporin alone in a theoretical cohort of 700,000 women, the approximate number of nonelective cesarean deliveries annually in the United States that occur during labor or after membrane rupture. Outcomes examined included endometritis, wound infection, sepsis, venous thromboembolism, and maternal death in the current pregnancy and uterine rupture, cesarean hysterectomy, and maternal death in subsequent pregnancies, including cost and quality-adjusted life-years for both pregnancies. Probabilities, utilities, and costs were derived from the literature, and a cost-effectiveness threshold was set at $100,000 per quality-adjusted life-year. Sensitivity analyses were used to determine the robustness of our results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Compared with cephalosporin alone for prophylaxis, our model showed 16,100 fewer cases of endometritis, 17 fewer cases of sepsis, eight fewer cases of venous thromboembolism, and one fewer maternal death with azithromycin\u2013cephalosporin. Additionally, this strategy prevented 36 uterine ruptures and four cesarean hysterectomies in the subsequent pregnancy. Overall, the addition of azithromycin led to both lower costs and higher quality-adjusted life-years when compared with standard cephalosporin prophylaxis. In sensitivity analysis, we found that as long as the cost of azithromycin remained below $930 (baseline cost $27), it was cost-effective.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>For women who undergo cesarean delivery in labor or after membrane rupture, compared with cephalosporin alone, the addition of azithromycin to cesarean delivery infection prophylaxis is less costly and leads to better maternal outcomes in the index delivery and subsequent deliveries. These findings support the use of prophylactic azithromycin at the time of cesarean delivery.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000002333","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T19:13:36Z","timestamp":1511378016000},"page":"1279-1284","source":"Crossref","is-referenced-by-count":20,"title":["Adding Azithromycin to Cephalosporin for Cesarean Delivery Infection Prophylaxis"],"prefix":"10.1097","volume":"130","author":[{"given":"Ashley E.","family":"Skeith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy M.","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Methodius G.","family":"Tuuli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron B.","family":"Caughey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/01.AOG.0000124568.71597.ce","article-title":"Maternal morbidity associated with vaginal versus cesarean delivery","volume":"103","author":"Burrows","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R3-20230711","article-title":"Surgical site infection after cesarean delivery: incidence and risk factors at a US academic institution","author":"Moulton","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1086\/509827","article-title":"A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections","volume":"27","author":"Herwaldt","year":"2006","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1086\/650755","article-title":"Attributable costs of surgical site infection and endometritis after low transverse cesarean section","volume":"31","author":"Olsen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R6-20230711","first-page":"136","article-title":"Post-cesarean delivery fever and uterine rupture in a subsequent trial of labor","volume":"101","author":"Shipp","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1097\/AOG.0b013e3182238c31","article-title":"Use of prophylactic antibiotics in labor and delivery. Practice Bulletin No. 120. American College of Obstetricians and Gynecologists","volume":"117","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa1602044","article-title":"Adjunctive azithromycin prophylaxis for cesarean delivery","volume":"375","author":"Tita","year":"2016","journal-title":"N Engl J Med"},{"key":"R9-20230711","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067175","article-title":"The continuum of maternal sepsis severity: incidence and risk factors in a population-based cohort study","author":"Acosta","year":"2013","journal-title":"PLoS One"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1213\/ANE.0b013e3182a009c3","article-title":"Maternal sepsis mortality and morbidity during hospitalization for delivery: temporal trends and independent associations for severe sepsis","volume":"117","author":"Bauer","year":"2013","journal-title":"Anesth Analg"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ajog.2005.11.008","article-title":"Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality","volume":"194","author":"James","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R12-20230711","first-page":"1","article-title":"Births: final data for 2013","volume":"64","author":"Martin","year":"2015","journal-title":"Natl Vital Stat Rep"},{"key":"R13-20230711","first-page":"1","article-title":"Maternal morbidity for vaginal and cesarean deliveries, according to previous cesarean history: new data from the birth certificate, 2013","volume":"64","author":"Curtin","year":"2015","journal-title":"Natl Vital Stat Rep"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1067\/mob.2001.114855","article-title":"Maternal and neonatal outcomes after uterine rupture in labor","volume":"184","author":"Yap","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"36.e1","DOI":"10.1016\/j.ajog.2008.03.007","article-title":"Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery","volume":"199","author":"Clark","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/jog.12710","article-title":"Incidence and risk factors of sepsis mortality in labor, delivery and after birth: population-based study in the USA","volume":"41","author":"Al-Ostad","year":"2015","journal-title":"J Obstet Gynaecol Res"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1056\/NEJMoa040405","article-title":"Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery","volume":"351","author":"Landon","year":"2004","journal-title":"N Engl J Med"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3810\/pgm.1997.04.199","article-title":"Intravenous-to-oral antibiotic switch therapy. A cost-effective approach","volume":"101","author":"Cunha","year":"1997","journal-title":"Postgrad Med"},{"key":"R19-20230711","first-page":"932","article-title":"Cost-effectiveness of a trial of labor after previous cesarean","volume":"97","author":"Chung","year":"2001","journal-title":"Obstet Gynecol"},{"key":"R22-20230711","first-page":"1","article-title":"Deaths: final data for 2014","volume":"65","author":"Kochanek","year":"2016","journal-title":"Natl Vital Stat Rep"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1471-0528.2006.01069.x","article-title":"Chilean women's preferences regarding mode of delivery: which do they prefer and why?","volume":"113","author":"Angeja","year":"2006","journal-title":"BJOG"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/OLQ.0b013e31815b07dd","article-title":"Quality of life utilities for pelvic inflammatory disease health states","volume":"35","author":"Smith","year":"2008","journal-title":"Sex Transm Dis"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med Care"},{"key":"R26-20230711","first-page":"1","article-title":"Inpatient care for septicemia or sepsis: a challenge for patients and hospitals","author":"Hall","year":"2011","journal-title":"NCHS Data Brief"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.1996.03540140060028","article-title":"The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine","volume":"276","author":"Russell","year":"1996","journal-title":"JAMA"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.AOG.0000295868.43851.39","article-title":"Decreasing incidence of postcesarean endometritis with extended-spectrum antibiotic prophylaxis","volume":"111","author":"Tita","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R29-20230711","doi-asserted-by":"crossref","first-page":"751.e1","DOI":"10.1016\/j.ajog.2016.02.037","article-title":"A comparison of 3 antibiotic regimens for prevention of postcesarean endometritis: an historical cohort study","volume":"214","author":"Ward","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R30-20230711","doi-asserted-by":"crossref","first-page":"812.e1","DOI":"10.1016\/j.ajog.2015.01.015","article-title":"Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis","volume":"212","author":"Sutton","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R31-20230711","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/AOG.0000000000002129","article-title":"Economic evaluation of adjunctive azithromycin prophylaxis for cesarean delivery","volume":"130","author":"Harper","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R32-20230711","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1377\/hlthaff.27.3.759","article-title":"The triple aim: care, health, and cost","volume":"27","author":"Berwick","year":"2008","journal-title":"Health Aff (Millwood)"},{"key":"R34-20230711","first-page":"521","article-title":"Severe sepsis in managed care: analysis of incidence, one-year mortality, and associated costs of care","volume":"10","author":"Braun","year":"2004","journal-title":"J Manag Care Pharm"},{"key":"R35-20230711","first-page":"363","article-title":"All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries","volume":"18","author":"Lefebvre","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"R36-20230711","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/1471-0528.13601","article-title":"Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study","volume":"123","author":"Azad","year":"2016","journal-title":"BJOG"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201712000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T18:07:23Z","timestamp":1689098843000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201712000-00014"}},"subtitle":["A Cost-Effectiveness Analysis"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000002333","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}